Sanofi’s Dupixent partner Regeneron secured U.S. clearance for a pediatric chronic spontaneous urticaria label expansion, while Sanofi’s broader financial picture remained supported by earnings performance. The FDA approval covers children ages 2 to 11 who remain symptomatic despite antihistamine treatment. The regulatory gain adds to Dupixent’s already established CSU presence in adults and adolescents, and it reinforces Regeneron’s earnings drivers as investors track incremental indications and competitive positioning. Separately, Sanofi’s reported sales strength and positive quarterly performance arrived even as R&D pressure builds in the background, with a leadership transition also in motion. Together, the approval and earnings signal a near-term cash-flow advantage as Sanofi reorganizes priorities under a new CEO.